GC Genome reports over 90% detection of colorectal 바카라사이트 소울카지노 using blood test in international journal

[by Sung, Jae Jun] GC Genome, a liquid biopsy and clinical genomics company, announced on November 27 that the results of a blood-based colon 바카라사이트 소울카지노 screening study, conducted in collaboration with the research team led by Professor Byun Jeong-sik at Asan Medical Center in Seoul, have been published in the international journal American Journal of Gastroenterology (AJG).

The study, conducted in a cohort of 1,677 participants, including 302 patients diagnosed with colon 바카라사이트 소울카지노 and 108 with advanced adenomas, applied the artificial intelligence (AI)-based fragmentomics technology integrated in GC Genome's multi-바카라사이트 소울카지노 blood test, iCanSearch. The stated research aimed to improve the early detection rate by addressing the inconvenience commonly associated with traditional colonoscopies and the low patient compliance observed in fecal occult blood testing.

This study reports a sensitivity of 90.4% and a specificity of 94.7% for the diagnosis of colorectal cancer. Detection performance remains high, with rates of 84.2% for stage 1 colorectal cancer and 90.0% for early-stage cancer (T1N0), a stage noted as treatable by endoscopic resection. The assay also identified advanced adenomas, described as a ‘precancerous stage,’ with a sensitivity of 58.3%. GC Genome explained that diagnostic accuracy was consistent irrespective of cancer site or patient age, supporting its potential as a blood-based screening test.

"The expansion of the detection range beyond colorectal cancer to precancerous lesions is a meaningful advancement for early prevention and management. As the international validity of liquid biopsy and AI analysis technology has now been confirmed, we plan to broaden its application in colorectal cancer screening markets, including health screenings, and to actively pursue global expansion," a GC Genome official said.

Conversely, in September 2023, GC Genome launched ‘iCanSearch,’ an AI- and WGS-based multi-cancer early detection test. In 2026, iCanSearch is scheduled to expand the number of cancer types it can detect from six to ten.